Switzerland· 69789005
Rivaroxaban-Amlodipin-Mepha 20 mg/5 mg, Tabletten
A direct factor xa inhibitors product containing rivaroxabanum, amlodipinum, registered in Switzerland by Mepha Pharma AG and dispensed under Swissmedic category B.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
The record
At a glance
Swissmedic (Switzerland)- Active substance
- rivaroxabanum, amlodipinum
- Manufacturer
- Mepha Pharma AG
- Country
- Switzerland (CH)
- ATC code
- B01AF
- ATC class
- Direct factor Xa inhibitors
- Swissmedic category
- B
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B01AF
Direct factor xa inhibitors, as other registers publish it.
- SwitzerlandRivaroxaban-Amlodipin-Mepha 15 mg/10 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 15 mg/10 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 15 mg/5 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 15 mg/5 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 20 mg/10 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 20 mg/10 mg, TablettenMepha Pharma AG
- SwitzerlandRivaroxaban-Amlodipin-Mepha 20 mg/5 mg, TablettenMepha Pharma AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/79c52e5b-09b5-4ee6-aebe-616509b6f709 GET /v1/drugs/79c52e5b-09b5-4ee6-aebe-616509b6f709?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about rivaroxabanum, amlodipinum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.